Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06940349 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Interventional Study to Evaluate the Combination of Palbociclib + Sunitinib as a Treatment for Advanced Solid Tumors

Study acronym: COPS-01
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 23, 2025 (before its estimated January 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The goal of this clinical trial is to learn if a combination of Palbociclib and Sunitinib is safe and effective in various solid tumors. The main questions it aims to answer are: * Is the drugs combination safe for the participants? * Is the drug combination effective in all solid malignancies? It is a single arm study, phase 1b/2, dose escalation and expansion, to determine the safety, tolerability and initial efficacy of this combination. Participants will: * Take the drugs combination every day for 5 executive days, and 2 days of, in a 28 days cycle, for up to a year. * Visit the clinic once every 2 weeks for checkups and tests
Trial Details
NCT Number NCT06940349
Lead Sponsor Rabin Medical Center
Conditions
(from sponsor)		 Solid Tumors Refractory to Standard Therapy
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov